Tag: GIP/GLP-1 dual receptor agonist

  • Tirzepatide

    GIP/GLP-1 dual receptor agonist

    A dual GIP and GLP-1 receptor agonist FDA-approved as Mounjaro (T2DM, 2022) and Zepbound (obesity, 2023), producing greater weight loss than GLP-1-only agents.

    Abstract

    Tirzepatide (Mounjaro, Zepbound; CAS 2023788-19-2; molecular weight 4813.54) is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor co-agonist developed by Eli Lilly and approved by the FDA for type 2 diabetes (2022) and chronic weight management (2023). The compound is a 39-amino-acid synthetic peptide based on the GIP scaffold with modifications at positions enabling GLP-1 receptor agonism alongside GIP receptor activity. Mechanism is dual GIP/GLP-1 receptor agonism producing complementary effects: GIP engagement adds to GLP-1’s glucose-dependent insulin secretion and contributes to weight regulation through fat metabolism modulation; GLP-1 contributes the central satiety, gastric emptying, and glucagon suppression effects.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.